CMTM6和PD-L1在宫颈鳞癌组织中的表达及临床意义  

The Expression and Clinical Significance of CMTM6 and PD-L1 in Cervical Squamous Cell Carcinoma

作　　者：马艳[1] 李隆玉[1] 敖梅红[1] 卢朝霞 MA Yan;LI Longyu;AO Meihong(Jiangxi Maternal and Child Health Hospital,Nanchang,330006)

机构地区：[1]江西省妇幼保健院,330006

出　　处：《实用癌症杂志》2023年第12期2038-2042,2045,共6页The Practical Journal of Cancer

摘　　要：目的探讨CMTM6和PD-L1在宫颈鳞癌(CSCC)组织中的表达、相互关系及临床意义。方法采用免疫组化法检测20例正常子宫颈、26例子宫颈癌前病变和46例早期宫颈鳞癌组织中CMTM6和PD-L1表达,分析CMTM6和PD-L1表达与早期宫颈鳞癌临床病理特征及预后的关系。结果CMTM6在正常宫颈、宫颈癌前病变、宫颈鳞癌组织中高表达分别为0%(0/20)、11.54%(3/26)、60.87%(28/46),三者差异有统计学意义(χ^(2)=31.08,P<0.01);PD-L1在3组中高表达分别为10%(2/20)、15.38%(4/26)、71.74%(33/46),差异有统计学意义(χ^(2)=32.58,P<0.01)。McNemar检验CMTM6、PD-L1表达在早期宫颈鳞癌中差异无统计学意义(P>0.05);Kappa检验CMTM6和PD-L1在早期宫颈鳞癌中的表达呈一致性且密切相关(P<0.01,Kappa值0.472)。CMTM6高表达的早期宫颈鳞癌患者脉管癌栓、宮旁浸润和淋巴转移发生率增高(P<0.01),PD-L1表达则对其无明显影响(P>0.05);通过Kaplan-Meier分析,CMTM6高表达的早期宫颈鳞癌患者5年无病生存期下降,而PD-L1高表达的早期宫颈鳞癌患者5年无病生存期无明显改变。结论CMTM6和PD-L1在早期宫颈鳞癌患者中表达增高且两者呈一致性,CMTM6可能是早期宫颈鳞癌浸润、转移预警及生存预后评估的指标。Objective To explore the expression,correlation,and clinical significance of CMTM6 and PD-L1 in cervical squamous cell carcinoma(CSCC)patients.Methods Immunohistochemical staining was used to detect the expression of CMTM6 and PD-L1 in 20 normal cervical tissues,26 cervical precancerous lesions,and 46 early CSCC tissues.The relationship between the expression of CMTM6 and PD-L1 and the clinical pathological characteristics and prognosis of early CSCC was analyzed.Results The high expression of CMTM6 in normal cervical,cervical precancerous lesions,and CSCC groups was 0%(0/20),11.54%(3/26),and 60.87%(28/46)(χ^(2)=31.08,P<0.01).PD-L1 was highly expressed in 10%(2/20),15.38%(4/26),and 71.74%(33/46)of the 3 groups(χ^(2)=32.58,P<0.01).McNemar test showed no significant difference in the expression of CMTM6 and PD-L1 in early CSCC,P>0.05;Kappa test for consistency between the two.The expression of CMTM6 and PD-L1 is consistent and closely related in early CSCC.Elevated expression of CMTM6 increases the incidence of vascular emboli,periuterine infiltration,and lymphatic metastasis in early CSCC patients(P<0.01),PD-L1 expression has no significant effect on it(P>0.05).Through Kaplan Meier analysis,high expression of CMTM6 results in a decrease in five-year disease-free survival in early CSCC patients.However,when PD-L1 is highly expressed,there is no significant change in the five-year disease-free survival period of early CSCC patients.Conclusion The expression of CMTM6 and PD-L1 is increased and consistent in early CSCC patients,CMTM6 may be an indicator for early invasion,metastasis warning,and survival prognosis evaluation of CSCC.

关 键 词：宫颈鳞癌 趋化素样因子超家族蛋白6(CMTM6) 程序性死亡受体配体1(PD-L1) 无病生存期(DFS) 

分 类 号：R737.33[医药卫生—肿瘤]